Stem cell populations and methods of use
Populations of stem cells and methods for their isolation and use are provided. These stem cell populations comprise aldehyde dehydrogenase positive (ALDH br ) cells isolated from bone marrow, and ALDH br CD105 + cells derived from any stem cell source. These populations may also comprise cells expressing such surface markers as CD34, CD38, CD41, CD45, CD105, CD133, CD135, CD117, and HLA-DR, and/or are substantially free from such cell surface markers as CD3, CD7, CD 10, CD 13, CD 14, C1319, CD33, CD35, CD56, CD 127, CD 138, and glycophorin A. The population may also comprise cells expressing CD90. The stem cell populations of the invention are isolated from a stem cell source such as bone marrow, peripheral blood, umbilical cord blood, and fetal liver. Methods of the invention comprise isolating and purifying stem cell populations from stem cell sources, and methods of using these cells to reconstitute, repair, and regenerate tissues.
1. A cell population of ALDH br stem cells, wherein at least 10% of the cells within said population express at least CD105, and wherein said population is capable of multilineage development.
2. The cell population of claim 1 , wherein said stem cells are derived from bone marrow.
3. The cell population of claim 1 , wherein at least 10% of the cells within said population also express at least one cell surface marker selected from the group consisting of CD34, CD38, CD41, CD45, CD117, CD133, HLA-DR, and combinations thereof, wherein said population is substantially free of cells expressing cell surface markers selected from the group consisting of CD3, CD7, CD10, CD13, CD14, CD19, CD33, CD35, CD56, CD127, CD138, glycophorin A, and combinations thereof, and wherein said population of cells is capable of multilineage development.
4. The cell population of claim 1 , wherein greater than about 60% of the cells within the population express the cell surface marker CD105.
5. The cell population of claim 1 , wherein at least 10% of the cells within the population are side scatter channel low (SSC lo ).
6. The cell population of claim 1 , wherein said population is capable of engrafting a mammal.
7. The cell population of claim 6 , wherein said population is capable of engrafting hematopoietic cells.
8. The cell population of claim 6 , wherein said population is capable of engrafting a SCID/NOD mouse spleen with human B cell precursors.
9. The cell population of claim 6 , wherein said population is capable of engrafting human thymus tissue transplanted into SCID/hu Thy mice with T cell precursors.
10. The cell population of claim 9 , wherein said T cell precursors are capable of developing into T cells expressing CD4 or CD8.
11. The cell population of claim 6 , wherein said population is capable of engrafting mesenchymal cells.
12. The cell population of claim 11 , wherein said population is capable of engrafting tissue selected from the group consisting of bone marrow stroma, bone, cartilage, tendon, fat, smooth muscle, cardiac muscle, skeletal muscle, nerves, oligodendrocytes, fibroblasts, endothelium, and combinations thereof.
13. A composition comprising the cell population of claim 1 in a pharmacologically acceptable carrier.
14. A cell population of bone-marrow-derived, ALDH br stem cells, wherein said cells are capable of multilineage development.
15. The cell population of claim 14 , wherein at least 10% of the cells within said population express a cell surface marker selected from the group consisting of CD34, CD38, CD41, CD45, CD105, CD117, CD133, HLA-DR, and combinations thereof, wherein said population is substantially free of cells expressing cell surface markers selected from the group consisting of CD3, CD7, CD10, CD13, CD14, CD19, CD33, CD35, CD56, CD127, CD138, glycophorin A, and combinations thereof, and wherein said population of cells is capable of multilineage development.
16. The cell population of claim 15 , wherein at least 10% of the cells within said population express at least CD105.
17. The cell population of claim 16 , wherein at least 40% of the cells within said population express at least CD105.
18. The cell population of claim 14 , wherein at least 10% of the cells within the population are side scatter channel low (SSC lo ).
19. The cell population of claim 14 , wherein said population is capable of engrafting a mammal.
20. The cell population of claim 19 , wherein said population is capable of engrafting hematopoietic cells.
21. The cell population of claim 19 , wherein said population is capable of engrafting a SCID/NOD mouse spleen with human B cell precursors.
22. The cell population of claim 19 , wherein said population is capable of engrafting human thymus tissue transplanted into SCID/hu Thy mice with T cell precursors.
23. The cell population of claim 22 , wherein said T cell precursors are capable of developing into T cells expressing CD4 or CD8.
24. The cell population of claim 19 , wherein said population is capable of engrafting mesenchymal cells.
25. The cell population of claim 24 , wherein said population is capable of engrafting tissue selected from the group consisting of bone marrow stroma, bone, cartilage, tendon, fat, smooth muscle, cardiac muscle, skeletal muscle, nerves, oligodendrocytes, fibroblasts, endothelium, and combinations thereof.
26. A composition comprising the cell population of claim 14 in a pharmacologically acceptable carrier.